Dr. McCabe, I had the privilege of serving on the Ontario Health Technology Advisory Committee for a number of years back when Les Levin was involved, and your cost-effectiveness research has been quite helpful.
You made a comment in your report about how we would start up. I have five minutes and three questions, just so you can time your answers. There is advice for us in this report as to how we would start up the formulary. I think you said a number would be grandfathered in. Is there another system like the one in the U.K. or another that you would recommend we adopt as our initial formulary while we sort through who would be developing...? This is for general-purpose drugs and not just for orphan or rare disease drugs.